Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
The latest announcement is out from Evolus ( (EOLS) ).
On September 8, 2025, Evolus, Inc. announced the appointment of Tatjana Mitchell as its new Chief Financial Officer. With over 20 years of experience in strategic and operational finance, Mitchell is expected to play a crucial role in driving revenue growth and operational excellence as Evolus expands its portfolio and global footprint. Her previous roles include Senior Vice President of Corporate Finance at Experian and CFO at Zulily, where she demonstrated a strong track record in financial management and strategic execution.
The most recent analyst rating on (EOLS) stock is a Hold with a $7.50 price target. To see the full list of analyst forecasts on Evolus stock, see the EOLS Stock Forecast page.
Spark’s Take on EOLS Stock
According to Spark, TipRanks’ AI Analyst, EOLS is a Neutral.
Evolus faces significant financial challenges, with negative profitability and reliance on external financing weighing heavily on its score. Technical indicators suggest a bearish trend, and valuation concerns persist due to ongoing losses. While the earnings call and corporate events provide some positive outlook, immediate market challenges and decreased demand for key products limit the overall score.
To see Spark’s full report on EOLS stock, click here.
More about Evolus
Evolus, Inc. is a global performance beauty company focused on redefining the aesthetic injectable market for the next generation of beauty consumers. The company is known for its flagship products, Jeuveau® and Evolysse™, which are dedicated to aesthetics and injectable hyaluronic acid gels, respectively.
Average Trading Volume: 1,367,355
Technical Sentiment Signal: Sell
Current Market Cap: $495.5M
For an in-depth examination of EOLS stock, go to TipRanks’ Overview page.